Positive Results from Registrational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) in Advanced Endometrial Carcinoma Published in the Journal of Clinical Oncology - The Trentonian

Positive Results from Registrational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) in Advanced Endometrial Carcinoma Published in the Journal of Clinical Oncology  The Trentonian

Comments

Post a Comment

Popular posts from this blog

Advanced Heart Failure Therapies for Adults With Congenital Heart Disease: JACC State-of-the-Art Review

Image
wolff white syndrome :: Article Creator Stopping The Bias Snowball, Before It Kills Your Patient I arrived on scene perhaps ten minutes behind the first-in crew and the shift supervisor. Both the crew paramedic and the supervisor were knowledgeable, experienced providers. A school nurse was there as well, providing background info on our patient; a 16-year-old student with a history of asthma in severe distress. Our patient was in bad shape. She had severe difficulty breathing, tachycardia, was pale and diaphoretic, and you could hear the wheezes and rhonchi from 10 feet away. Her eyes had that unfocused, half-lidded stare that signals impending loss of consciousness and respiratory arrest. No doubt about it, she was sick and getting worse. She hadn't responded to multiple doses of her Combivent inhaler, and the lead medic – one our our flight paramedics who was covering a shift on a ground unit that day – already had a DuoNeb in place on a ...
Read more

Numbness in the hands: Causes and treatments

Image
coronary artery disease :: Article Creator Coronary Artery Disease Testing After Initial Heart Failure Hospitalization Aids Outcomes Coronary artery disease (CAD) testing within 90 days of hospitalization for heart failure is associated with a lower risk for heart failure readmission or all-cause mortality, according to a study published online Jan. 18 in the Journal of General Internal Medicine. Cheng‑Wei Huang, M.D., from Kaiser Permanente Los Angeles Medical Center, and colleagues assessed whether widespread CAD testing in patients with new-onset heart failure leads to improved outcomes. The analysis included 2,729 adults with new-onset heart failure with reduced ejection fraction hospitalized within one of 15 Kaiser Permanente Southern California medical centers between 2016 and 2021. The researchers found that 54.5 percent of patients received CAD testing, and after a median of 1.8 years, the testing group had a reduced risk for heart f...
Read more

Treating Cardiac Edema

Image
achondroplasia genetics :: Article Creator Vosoritide Beneficial For Children Younger Than 5 Years With Achondroplasia WEDNESDAY, Dec. 27, 2023 (HealthDay News) — For children with achondroplasia, vosoritide is associated with a gain in the change in height Z score from baseline and a mild adverse event profile, according to a study published in the January issue of The Lancet Child & Adolescent Health. Ravi Savarirayan, M.D., from the Royal Children's Hospital at the University of Melbourne in Australia, and colleagues conducted a double-blind, randomized phase 2 trial in 16 hospitals across Australia, Japan, the United Kingdom, and the United States to examine the safety and efficacy of vosoritide in children younger than 60 months with a clinical diagnosis of achondroplasia confirmed by genetic testing. Participants were enrolled into three cohorts based on age at screening: 24 to 59 months, 6 to 23 months, and 0 to 5 months (cohorts 1,...
Read more